Advertisement

Diabetes and Advanced Glycation End Products

  • Helen Vlassara
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Prolonged exposure to hyperglycemia is now recognized as the primary causal factor in the majority of diabetic complications (1,2). Indeed, glucose has a wide range of effects on normal cell function that are reversible and reflect the transient nature of hyperglycemia (3,4). Significantly, many of the effects of hyperglycemia are irreversible and can cause progressive, cumulative cell dysfunction (5). This suggests that persistent rather than transient, acute metabolic changes are of pivotal importance in diabetic complications. Among the irreversible changes that occur as a direct result of hyperglycemia is the formation of advanced glycation end products (AGE), which have a range of chemical, cellular, and tissue effects and act as mediators, not only of diabetic complications but also of widespread changes associated with aging.

Keywords

Diabetic Nephropathy Advanced Glycation Endproducts Nonenzymatic Glycosylation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pirart J. Diabetes mellitus and its degenerative complications: prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1978;188: 252–263.Google Scholar
  2. 2.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329: 977–986.CrossRefGoogle Scholar
  3. 3.
    Ruderman N, Williamson J, Brownlee M, eds. Hyperglycemia, Diabetes and Vascular Disease. American Physiological Society, Oxford University Press, New York, 1992.Google Scholar
  4. 4.
    King GL, Kunisaki M, Nishio Y, Inoguchi T, Shiba T, Xia P. Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes 1996;45(Supp13):S105–S108.Google Scholar
  5. 5.
    Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987;36:808–812.PubMedCrossRefGoogle Scholar
  6. 6.
    Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836–842.PubMedCrossRefGoogle Scholar
  7. 7.
    Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994;343:1519–1522.PubMedCrossRefGoogle Scholar
  8. 8.
    Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994;94:110–117.PubMedCrossRefGoogle Scholar
  9. 9.
    Brownlee M, Vlassara H, Cerami A. Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes. Diabetes 1984;33:532–535.PubMedCrossRefGoogle Scholar
  10. 10.
    Watkins NG, Thorpe SR, Baynes JW. Glycation of amino groups in protein. Studies on the specificity of modification of RNase by glucose. J Biol Chem 1985;260:10,629–10,636.Google Scholar
  11. 11.
    Tsilibary EC, Charonis AS, Reger LA, Wohlhueter RM, Furcht LT. The effect of nonenzymatic glucosylation on the binding of the main noncollagenous NC1 domain to type IV collagen. J Biol Chem 1988;263:4302–4308.PubMedGoogle Scholar
  12. 12.
    Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994;91:4766–4770.PubMedCrossRefGoogle Scholar
  13. 13.
    Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995;270:10,828–10,832.Google Scholar
  14. 14.
    Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434–6438.PubMedCrossRefGoogle Scholar
  15. 15.
    Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441–9445.PubMedCrossRefGoogle Scholar
  16. 16.
    Stitt AW, Vlassara H, Bucala R. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann NY Acad Sci 1997;811:115–129.PubMedCrossRefGoogle Scholar
  17. 17.
    Stitt AW, He C, Friedman S, et al. Elevated AGE-modified ApoB in the sera of euglycemic, normolipidemic patients with atherosclerosis. Mol Med 1997;3:617–627.PubMedGoogle Scholar
  18. 18.
    Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentosederived crosslink from aging human collagen. J Clin Invest 1990;85:380–384.PubMedCrossRefGoogle Scholar
  19. 19.
    Monnier VM, Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 1981;211:491–493.PubMedCrossRefGoogle Scholar
  20. 20.
    Kohn RR, Cerami A, Monnier VM. Collagen aging in vitro by nonenzymatic glycosylation and browning. Diabetes 1984;33:57–59.PubMedCrossRefGoogle Scholar
  21. 21.
    Harding JJ, Crabbe MJC. The lens: development proteins, metabolism and cataract. In: Davson H, ed. The Eye, vol lb. Academic, New York, 1984, pp. 207–492.Google Scholar
  22. 22.
    Stevens VJ, Rouzer CA, Monnier VM, Cerami A. Diabetic cataract formation: potential role of glycosylation of lens crystallins. Proc Natl Acad Sci USA 1978;75:2918–2922.PubMedCrossRefGoogle Scholar
  23. 23.
    Monnier VM, Stevens VJ, Cerami A. The browning reaction of proteins with glucose. Arch Biochem 1979;24:157–178.Google Scholar
  24. 24.
    Matsumoto K, Ikeda K, Horiuchi S, Zhao H, Abraham EC. Immunochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lenses. Biochem Biophys Res Commun 1997;241:352–354.PubMedCrossRefGoogle Scholar
  25. 25.
    Stitt AW, Moore J, Sharkey JA, et al. Advanced glycation endproducts in vitreous: structural and functional implications for diabetic vitreopathy. Invest Ophthalmol Vis Sci 1998;39:2517–2523.PubMedGoogle Scholar
  26. 26.
    Charonis AS, Tsilbary EC. Structural and functional changes of laminin and type IV collagen after nonenzymatic glycation. Diabetes 1992;41(Suppl 2):49–51.PubMedGoogle Scholar
  27. 27.
    Knecht R, Leber R, Hasslacher C. Degradation of glomerular basement membrane in diabetes. I. Susceptibility of diabetic and nondiabetic basement membrane to proteolytic degradation of isolated glomeruli. Res Exp Med (Berl) 1987;187:323–328.CrossRefGoogle Scholar
  28. 28.
    Paul RG, Bailey AJ. Glycation of collagen: the basis of its central role in the late complications of aging and diabetes. Int J Biochem Cell Biol 1996;28:1297–1310.PubMedCrossRefGoogle Scholar
  29. 29.
    Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 1992;267:12,404–12,407.Google Scholar
  30. 30.
    Hammes HP, Weiss A, Hess S, et al. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest 1996;75:325–338.PubMedGoogle Scholar
  31. 31.
    Tarsio JF, Reger LA, Furcht LT. Decreased interaction of fibronectin, type IV collagen, and heparin due to nonenzymatic glycation. Implications for diabetes mellitus. Biochemistry 1987;26:1014–1020.PubMedCrossRefGoogle Scholar
  32. 32.
    Tarsio JF, Reger LA, Furcht LT. Molecular mechanisms in basement membrane complications of diabetes. Alterations in heparin, laminin, and type IV collagen association. Diabetes 1988;37:532–539.PubMedCrossRefGoogle Scholar
  33. 33.
    Bucala R, Model P, Cerami A. Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci USA 1984; 81:105–109.PubMedCrossRefGoogle Scholar
  34. 34.
    Lee AT, Cerami A. Elevated glucose 6-phosphate levels are associated with plasmid mutations in vivo. Proc Natl Acad Sci USA 1987;84:8311–8314.PubMedCrossRefGoogle Scholar
  35. 35.
    Bucala R, Model P, Russel M, Cerami A. Modification of DNA by glucose 6-phosphate induces DNA rearrangements in an Escherichia coli plasmid. Proc Natl Acad Sci USA 1985;82:8439–8442.PubMedCrossRefGoogle Scholar
  36. 36.
    Lee AT, Plump A, DeSimone C, Cerami A, Bucala R. A role for DNA mutations in diabetes-associated teratogenesis in transgenic embryos. Diabetes 1995;44:20–24.PubMedCrossRefGoogle Scholar
  37. 37.
    Pushkarsky T, Rourke L, Spiegel LA, Seldin MF, Bucala Molecular characterization of a mouse genomic element mobilized by advanced glycation endproduct modified-DNA (AGE-DNA). Mol Med 1997;3:740–749.PubMedGoogle Scholar
  38. 38.
    Jacobson EL, Cervantes-Laurean D, Jacobson MK. ADP-ribose in glycation and glycoxidation reactions. Adv Exp Med Biol 1997;419:371–379.PubMedCrossRefGoogle Scholar
  39. 39.
    Cervantes-Laurean D, Jacobson EL, Jacobson MK. Glycation and glycoxidation of histones by ADPribose. J Biol Chem 1996;271:10,461–10,469.Google Scholar
  40. 40.
    Gugliucci A, Bendayan M. Histones from diabetic rats contain increased levels of advanced glycation end products. Biochem Biophys Res Commun 1995;212:56–62.PubMedCrossRefGoogle Scholar
  41. 41.
    Mills JL. Malformations in infants of diabetic mothers. Teratology 1982;25:385–394.PubMedCrossRefGoogle Scholar
  42. 42.
    Mills JL, Baker L, Goldman AS. Malformations in infants of diabetic mothers occur before the seventh gestational week. Implications for treatment. Diabetes 1979;28:292–293.PubMedCrossRefGoogle Scholar
  43. 43.
    Mills JL, Knopp RH, Simpson JL, et al. Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med 1988;318:671–676.PubMedCrossRefGoogle Scholar
  44. 44.
    Gardiner TA, Stit AW, Archer DB. Endocytosis by retinal vascular endothelial cells increases in early diabetes: a quantitative EM study in STZ-diabetic rats. Lab Invest 1995;72:439–444.PubMedGoogle Scholar
  45. 45.
    S titt AW, Chakravarthy U, Archer DB, Gardiner TA. Increased endocytosis of retinal vascular endothelial cells grown in hyperglycemia is modulated by inhibitors of non-enzymatic glycosylation. Diabetologia 1995;38:1271–1275.PubMedCrossRefGoogle Scholar
  46. 46.
    Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997;46(Suppl 2): S 19–525.Google Scholar
  47. 47.
    Miyata T, Oda O, Inagi R, et al. Beta 2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993;92:1243–1252.PubMedCrossRefGoogle Scholar
  48. 48.
    Miyata T, Inagi R, Iida Y, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994;93:521–528.PubMedCrossRefGoogle Scholar
  49. 49.
    Dolhofer-Bliesener R, Lechner B, Gerbitz KD. Possible significance of advanced glycation end products in serum in end-stage renal disease and in late complications of diabetes. Eur J Clin Chem Clin Biochem 1996;34:355–361.PubMedGoogle Scholar
  50. 50.
    Shinohara M, Thornalley PJ, Giardino I, et al. Overexpression of glyoxalase-1 in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemiainduced increases in macromolecular endocytosis. J Clin Invest 1998;101:1142–1147.PubMedCrossRefGoogle Scholar
  51. 51.
    Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997;94:13,915–13,920.Google Scholar
  52. 52.
    Founds H, Giordano D, Stitt AW, et al. Tobacco smoke is a source of advanced glycation endproducts (AGEs): possible role in the accelerated vascular disease of smokers. J Invest Med 1996;44: A200.Google Scholar
  53. 53.
    Nicholl ID, Stitt AW, Moore JE, Ritchie AJ, Archer DB, Bucala R. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med 1998;4:594–601.PubMedGoogle Scholar
  54. 54.
    Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997;94:6474–6479.PubMedCrossRefGoogle Scholar
  55. 55.
    Lithner F, Asplund K, Eriksson S, Hagg E, Strand T, Wester PO. Clinical characteristics in diabetic stroke patients. Diabetes Metab 1988;14:15–19.Google Scholar
  56. 56.
    Pyorala, K. Diabetes and coronary artery disease: what a coincidence? J Cardiovasc Pharmaco11990;16: S 8-S 14.Google Scholar
  57. 57.
    Ruderman NB, Haudenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984;26: 273–412.CrossRefGoogle Scholar
  58. 58.
    Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801–809.PubMedCrossRefGoogle Scholar
  59. 59.
    Mahley RW, Innerarity TL, Weisgraber KN, Oh SY. Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoprotein B. J Clin Invest 1979;64:743–750.PubMedCrossRefGoogle Scholar
  60. 60.
    Mahley RW, Innerarity TL, Pitas RE, Weisgraber KH, Brown JH, Gross E. Inhibition of lipoprotein binding to surface receptors of fibroblasts following selective modification of arginyl residues in apoprotein B. J Biol Chem 1987;252:7279–7287.Google Scholar
  61. 61.
    Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoproteins producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979;76:333–337.PubMedCrossRefGoogle Scholar
  62. 62.
    Fogelman AM, Haberland ME, Seager J, Hokom M, Edwards PA. Factors regulating the activities of the low density lipoprotein receptor and the scavenger receptor on human monocytes and macrophages. J Lipid Res 1980;22:1131–1141.Google Scholar
  63. 63.
    Palinski W, Koschinsky T, Butler SW, et al. Immunological evidence for the presence of advanced glycosylation endproducts products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 1995;15:571–582.PubMedCrossRefGoogle Scholar
  64. 64.
    Kume S, Takeya M, Mori T, et al. Immunohistochemical and ultrastructural detection of advanced glycation endproducts in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995;147:654–667.PubMedGoogle Scholar
  65. 65.
    Nakamura Y, Horii Y, Nishino T, et al. Immunohistochemical localization of advanced glycosylation endproducts (AGEs) in coronary atheroma and cardiac tissue in diabetes. Am JPatho11993;143:1649–1656.Google Scholar
  66. 66.
    Sima A, Popov D, Starodub O, et al. Pathobiology of the heart in experimental diabetes: immunolocalization of lipoproteins, immunoglobulin G, and advanced glycation endproducts proteins in diabetic and/or hyperlipidemic hamster. Lab Invest 1997;77:3–18.PubMedGoogle Scholar
  67. 67.
    Niwa T, Katsuzaki T, Miyazaki S, et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997;99:1272–1280.PubMedCrossRefGoogle Scholar
  68. 68.
    Horiuchi S, Sano H, Higashi T, et al. Extra- and intracellular localization of advanced glycation endproducts in human atherosclerotic lesions. Nephrol Dial Transplant 1996;11(Suppl 5):81–86.PubMedCrossRefGoogle Scholar
  69. 69.
    Li YM, Mitsuhashi T, Wojciehowicz D, et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors. Relationship of p60 to OST-48 and 80K-H membrane proteins. Proc Natl Acad Sci USA 1996;93:11,047–11,052.Google Scholar
  70. 70.
    Stitt AW, He C, Burke G, Li YM, Vlassara H. The advanced glycation endproduct (AGE) receptor complex: characterisation in micro- and macrovascular endothelium. Diabetes 1997;46:53A.Google Scholar
  71. 71.
    Vlassara H, Bucala R, StrikerL. Pathogenic effects of advanced glycosylation endproducts: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994;70:138–151.PubMedGoogle Scholar
  72. 72.
    ArakiN, Higashi T, Mori T, et al. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. EurJ Biochem 1995;230:408–415.CrossRefGoogle Scholar
  73. 73.
    Dobrian A, Lazar V, Tirziu D, Simionescu M. Increased macrophage uptake of irreversibly glycated albumin modified-low density lipoproteins of normal and diabetic subjects is mediated by non-saturable mechanisms. Biochim Biophys Acta 1996;1317:5–14.PubMedCrossRefGoogle Scholar
  74. 74.
    Seftel AD, Vaziri ND, Ni Z, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997;50:1016–1026.Google Scholar
  75. 75.
    Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432–438.PubMedCrossRefGoogle Scholar
  76. 76.
    Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and ageing complications. Proc Natl Acad Sci USA 1992;89:12,043–12,047.Google Scholar
  77. 77.
    Stern DM, Esposito C, Gerlach H, et al. Endothelium and regulation of coagulation. Diabetes Care 1991;14:160–166.PubMedCrossRefGoogle Scholar
  78. 78.
    Kirstein M, Aston C, Hintz R, Vlassara H. Receptorspecific induction of insulin-like growth factor Iinhuman monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992;90: 439–446.PubMedCrossRefGoogle Scholar
  79. 79.
    Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995; 1:447–456.PubMedGoogle Scholar
  80. 80.
    Dyck PJ, Hansen S, Karnes J, et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci USA 1985;82:2513–2517.PubMedCrossRefGoogle Scholar
  81. 81.
    Vinik AI, Holland MT, Le Beau JM, Liuzi FJ, Stansberry KB, Colen LB. Diabetic neuropathies. Diabetes Care 1992;15:1926–1975.PubMedCrossRefGoogle Scholar
  82. 82.
    Soulis Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin induced rat. Diabetes 1991;40:1328–1334.CrossRefGoogle Scholar
  83. 83.
    La Selva M, Beltramo E, Passera P, Porta M, Molinatti GM. The role of endothelium in the pathogenesis of diabetic microangiopathy. Acta Diabetol 1993;30:190–200.PubMedCrossRefGoogle Scholar
  84. 84.
    Osterby R. Early phases in the development of diabetic glomerulopathy. Acta Med Scand 1975;574 (Suppl 1):13–77.Google Scholar
  85. 85.
    Osterby R, Anderson MJF, Gundersen HJG, Jorgensen HE, Mogensen CE, Parving HH. Quantitative study on glomerular ultrastructure in type I diabetes with incipient nephropathy. Diabetes Nephrop 1983;3:95–100.Google Scholar
  86. 86.
    Mogensen CE. Renal function changes in diabetes. Diabetes 1976;25(Suppl 2):872–879.PubMedGoogle Scholar
  87. 87.
    Gugliucci A, Bendayan M. Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin induced diabetic rats. An ultrastructural study using colloidal gold cytochemistry. J Histochem Cytochem 1995;43:591–600.PubMedCrossRefGoogle Scholar
  88. 88.
    Gugliucci A, Bendayan M. Renal fate of circulating advanced glycation end products (AGE): evidence for reabsorption and catabolism of AGE peptides by renal proximal tubular cells. Diabetologia 1995; 39:149–160.CrossRefGoogle Scholar
  89. 89.
    Makino H, Shikata K, Hironaka K, et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 1995;48:517–526.PubMedCrossRefGoogle Scholar
  90. 90.
    Pugliese G, Pricci F, Romeo G, et al. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997;46: 1881–1887.PubMedCrossRefGoogle Scholar
  91. 91.
    Yamauchi A, Takei I, Makita Z, et al. Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats. Diabetes Res Clin Pract 1997;34:127–133.PubMedCrossRefGoogle Scholar
  92. 92.
    Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994;91: 9436–9440.PubMedCrossRefGoogle Scholar
  93. 93.
    Kahn HA, Moorhead HB. Statistics on Blindness in the Model Reporting Area, 1969–1970. US Department of Health, Education, and Welfare Publication No. (NIH) 73–427, US Government Printing Office, Washington, DC, 1973.Google Scholar
  94. 94.
    Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997;150:523–531.PubMedGoogle Scholar
  95. 95.
    Brownlee M, Vlassara H, Cerami A. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315–1321.PubMedCrossRefGoogle Scholar
  96. 96.
    HammesHP,WellensiekB,KlotingI,SickelE,BretzelRG,BrownleeM.Therelationshipofglycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster. Diabetologia 1998;41:165–170.CrossRefGoogle Scholar
  97. 97.
    Clements RS Jr, Robison WG Jr, Cohen MP. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J Diabetes Comp 1998;12:28–33.CrossRefGoogle Scholar
  98. 98.
    Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991;88:11,555–11,558.Google Scholar
  99. 99.
    Hammes HP, Ali SS, Uhlmann M, et al. Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. Diabetologia 1995;38:269–273.PubMedCrossRefGoogle Scholar
  100. 100.
    Hammes HP, Strodter D, Weiss A, Bretzel RG, Federlin K, Brownlee M. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 1995;38: 656–660.PubMedCrossRefGoogle Scholar
  101. 101.
    Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991;174:931–939.PubMedCrossRefGoogle Scholar
  102. 102.
    Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet derived growth factor. Proc Natl Acad Sci USA 1992;89:2873–2877.PubMedCrossRefGoogle Scholar
  103. 103.
    Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998;47:945–952.PubMedCrossRefGoogle Scholar
  104. 104.
    Chibber R, Molinatti PA, Rosatto N, Lambourne B, Kohner EM. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia 1997;40:156–164.PubMedCrossRefGoogle Scholar
  105. 105.
    Preissner KT, Kanse SM, Hammes HP. Integrin chatter and vascular function in diabetic retinopathy. Horm Metab Res 1997;29:643–645.PubMedCrossRefGoogle Scholar
  106. 106.
    Ruggiero-Lopez D, Rellier N, Lecomte M, Lagarde M, Wiernsperger N. Growth modulation of retinal microvascular cells by early and advanced glycation products. Diabetes Res Clin Pract 1997;34:135–142.PubMedCrossRefGoogle Scholar
  107. 107.
    Kalfa TA, Gerritsen ME, Carlson EC, Binstock AJ, Tsilibary EC. Altered proliferation of retinal microvascular cells on glycated matrix. Invest Ophthalmol Vis Sci 1995;36:2358–2367.PubMedGoogle Scholar
  108. 108.
    Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998;101:1219–1224.PubMedCrossRefGoogle Scholar
  109. 109.
    Hirata C, Nakano K, Nakamura N, et al. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. Biochem Biophys Res Commun 1997;236:712–715.PubMedCrossRefGoogle Scholar
  110. 110.
    Yamaguishi Si, Yonekura H, Yamamoto Y, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997;272:8723–8730.Google Scholar
  111. 111.
    Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and II-l induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988;240:1546–1548.PubMedCrossRefGoogle Scholar
  112. 112.
    Hasegawa G, Nakano K, Sawada M, et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991;40:1007–1012.PubMedCrossRefGoogle Scholar
  113. 113.
    Imani F, Horii Y, Suthanthiran M, et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med 1993;178:2165–2172.PubMedCrossRefGoogle Scholar
  114. 114.
    Yui S, Sasaki T, Araki N, Horiuchi S, Yamazaki M. Induction of macrophage growth by advanced glycation end products of the Maillard reactions. J Immunol 1994;152:1943–1949.PubMedGoogle Scholar
  115. 115.
    Vlassara H, Brownlee M, Cerami A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 1986;164:1301–1309.PubMedCrossRefGoogle Scholar
  116. 116.
    RadoffS,CeramiA,VlassaraH.Isolationofsurfacebindingproteinspecificforadvancedglycosylation end products from mouse macrophage-derived cell line RAW 264.7. Diabetes 1990;39:1510–1518.CrossRefGoogle Scholar
  117. 117.
    Yang Z, Makita Z, Horii Y, et al. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage scavenger receptor for glucose modified proteins. J Exp Med 1991;174:515–524.PubMedCrossRefGoogle Scholar
  118. 118.
    Vlassara H, Li YM, Imani F, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995; 1:634–646.PubMedGoogle Scholar
  119. 119.
    Li JJ, Dickson D, Hof PR, Vlassara H. Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis. Mol Med 1998;4:46–60.PubMedGoogle Scholar
  120. 120.
    Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489–497.PubMedCrossRefGoogle Scholar
  121. 121.
    Schmidt AM, Hasu M, Popov D, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating age proteins. Proc Natl Acad Sci USA 1994;91;8807–8811.PubMedCrossRefGoogle Scholar
  122. 122.
    Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morino Y. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J Biol Chem 1988;263:14,819–14,825.Google Scholar
  123. 123.
    Mackic J, Stins M, McComb J, et al. Human blood-brain barrier receptors for Aβ 1–40. J Clin Invest 1998;102:734–743.PubMedCrossRefGoogle Scholar
  124. 124.
    Schmidt AM, Vianna M, Gerlach M, et. al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992;267:14,987–14,997.Google Scholar
  125. 125.
    Li YM, Tan AX, Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nature Med 1995;1:1057–1061.PubMedCrossRefGoogle Scholar
  126. 126.
    Sano H, Higashi T, Matsumoto K, et al. Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products. J Biol Chem 1998;273:8630–8637.PubMedCrossRefGoogle Scholar
  127. 127.
    Horiuchi S, Higashi T, Ikeda K, et al. Advanced glycation endproducts and their recognition by macrophage and macrophage-derived cells. Diabetes 1996;45(Suppl 3):S73–S76.Google Scholar
  128. 128.
    Sava G. Pharmacological aspects and therapeutic applications of lysozymes. In: Jolies P, ed. Lysozymes: Model Enzymes in Biochemistry and Biology. Birkhauser Verlag, Basel, Switzerland, 1996, pp. 433–449.CrossRefGoogle Scholar
  129. 129.
    Mitsuhashi T, Li YM, Fishbane S, Vlassara H. Depletion of reactive advanced glycation endproducts from diabetic uremic sera by a lysozyme-linked matrix. J Clin Invest 1997;100:847–854.PubMedCrossRefGoogle Scholar
  130. 130.
    Zheng F, Cai W, Mitsuhashi T, Vlassara H. Enhanced in vivo turnover of advanced glycation endproducts and suppression of cell activation by lysozyme protects against diabetic kidney injury. 2001, in press.Google Scholar
  131. 131.
    Zheng F, He C, Li J, Vlassara H. In vivo treatment of diabetic mice (NOD and db/db) with lysozyme (LZ) enhances renal clearance of glycoxidation products and prevents albuminuria. Diabetes 2000;49:A161.Google Scholar
  132. 132.
    Cai W, Crandall JP, Oberstein R, Gao Q-D, Vlassara H. Inflammatory gene-activation and tissue crosslink formation are properties of dietary glycotoxins: role of common foods in tissue injury and diabetic complications. Diabetes 2000;49:A308.Google Scholar
  133. 133.
    Chen F, Crandall J, Zhu L, Gao Q, Vlassara H. Overexpression of human recombinant lysozyme (huLZ) by macrophages leads to enhanced glycotoxin uptake and clearance without cell activation; a new model approach for the prevention of diabetic complications. Diabetes 2000;49:A54.Google Scholar
  134. 134.
    Vlassara H, Li J, Bohmart A, Zheng F. Lysozyme (LZ) is secreted by mesangial cells and inhibits glycoxidation-dependent glomerular gene dysregulation in vitro and in vivo: a novel defense mechanism against diabetic nephropathy. Diabetes 2000;49:A161.Google Scholar
  135. 135.
    Radoff S, Vlassara H, Cerami A. Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylated end products. Arch Biochem Biophys 1988;263:418–423.PubMedCrossRefGoogle Scholar
  136. 136.
    RadoffS,CeramiA,VlassaraH.Isolationofsurfacebindingproteinspecificforadvancedglycosylation end products from mouse macrophage-derived cell line raw 264.7. Diabetes 1990;39:1510–1518.CrossRefGoogle Scholar
  137. 137.
    Chang JC, Ulrich PC, Bucala R, Cerami A. Detection of an advanced glycosylation product bound to protein in situ. J Biol Chem 1985;260:7970–7974.PubMedGoogle Scholar
  138. 138.
    Kislinger T, Fu C, Qu W, et al. Nε-(carboxymethl)-lysine adducts of proteins are ligands for RAGE that activate cell signaling pathways, and modulate gene expression. J Biol Chem 1999;274:31,740–31,749.Google Scholar
  139. 139.
    Thornalley PJ. Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, mehtylglyoxal and oxidative stress. Endocrinol Metab 1996;3:149–166.Google Scholar
  140. 140.
    Vlassara H, Brownlee M, Cerami A. Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. Diabetes 1988;37:456–461.PubMedCrossRefGoogle Scholar
  141. 141.
    Vlassara H, MoldawerL, Chan C. Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. J Clin Invest 1989;84:1813–1820.PubMedCrossRefGoogle Scholar
  142. 142.
    Vlassara H. Advanced non-enzymatic tissue glycosylation: mechanism implicated in the complications associated with aging. In: Clegg M, O’Brien, S, eds. Molecular Biology of Aging. Alan R. Liss, New York, 1989, pp. 171–185.Google Scholar
  143. 143.
    Yang Z, Makita Z, Horii Y, et al. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 1991;174:515–524.PubMedCrossRefGoogle Scholar
  144. 144.
    Goh KC, Lim YP, Ong SH, et al. Identification of p90, a prominent tyrosine-phosphorylated protein in fibroblast growth factor stimulated cells, as 80K-H. J Biol Chem 1996;271:5832–5838.PubMedCrossRefGoogle Scholar
  145. 145.
    Vlassara H, Li YM, Imani F, et al. Identification of Galectin-3 as a high affinity binding protein for advanced glycation endproducts (AGE): a new member of the AGE-receptor complex. Mol Med 1995;1:634–646.PubMedGoogle Scholar
  146. 146.
    Stitt AW, Burke G, Chen F, McMullen CBT, Vlassara H. Advanced glycation end product receptor interactions on microvascular cells occur within caveolin-rich membrane domains. FASEB J 2000; 14:2390–2392.PubMedGoogle Scholar
  147. 147.
    He C, Zheng F, Stitt A, Striker L, Masakazu H, Vlassara H. Differential expression of renal AGE-receptor genes in NOD mice: possible role in NOD diabetic renal disease. Kidney Int 2000;58:1931–1940.PubMedCrossRefGoogle Scholar
  148. 148.
    He C, Stitt A, Striker L, Hatori M, Vlassara H. Low expression of AGE-receptor-1 in NOD mouse mesangial cells: possible link to diabetic nephropathy. J Am Soc Nephrol 1996;7:1871A.Google Scholar
  149. 149.
    He C, Koschinsky T, Buenting C, Vlassara H. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear AGE-receptor-1 and elevated serum AGE. 2001, submitted.Google Scholar
  150. 150.
    He C, Koschinsky T, Sabol J, Buenting C, Liu C, Vlassara H. Mononuclear (MN) cell AGE receptor1(AGE-Rl) mRNA expression and its relationship to diabetic complications. Diabetes 1997;46:8A.Google Scholar
  151. 151.
    Kadrofske M, Openo KP, Wang JL. The human LGALS3 (Galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch Biochem Biophys 1998;349:7–20.PubMedCrossRefGoogle Scholar
  152. 152.
    Landers HM, Tauras JM, Ogiste JS. Isolation of cDNAs encoding a substate for protein kinase C: nucleotide sesquence and chromosomal mapping of the gene for a human 80K-H protein. J Biol Chem 1989;272:17,810–17,814.Google Scholar
  153. 153.
    Yamagata T, Tsuru T, Momoi M, et al. Genome organization of human 48-kDa oligosaccharryltranferase (DDOST). Genomics 1997;45:535–540.PubMedCrossRefGoogle Scholar
  154. 154.
    Poirier O, Nicaud V, Vionnet N, et al. Polymorphism screening of four genes encoding advanced glycation end product putative receptors: association study with nephropathy in type 1 diabetes patients. Diabetes J 2000, in press.Google Scholar
  155. 155.
    Hudson BI, Strickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene. Diabetes 1998;47:1155–1157.PubMedCrossRefGoogle Scholar
  156. 156.
    Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629–1632.PubMedCrossRefGoogle Scholar
  157. 157.
    Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998;47:1114–1120.PubMedCrossRefGoogle Scholar
  158. 158.
    Panagiotopoulos S, O’Brien RC, Bucala R, Cooper ME, Jerums G. Aminoguanidine has an antiatherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 1998;136:125–131.PubMedCrossRefGoogle Scholar
  159. 159.
    Nichols K, Mandel TE. Advanced glycosylation endproducts in experimental murine diabetic nephropathy: effect of iselt isografting and of aminoguanidine J Lab Invest 1989;60:486–491.Google Scholar
  160. 160.
    Ellis EN, Good BH. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 1991;40:1016–1019.PubMedCrossRefGoogle Scholar
  161. 161.
    Ido Y, Chang K, Ostrow E, et al. Aminoguanidine prevents regional blood flow increases in streptozotocin-diabetic rats. Diabetes 1990;39:93A.Google Scholar
  162. 162.
    Soulis Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin induced rat. Diabetes 1991;40:1328–1334.CrossRefGoogle Scholar
  163. 163.
    Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation endproduct inhibition by aminoguanidine. Diabetes 1992;41:26–28.PubMedCrossRefGoogle Scholar
  164. 164.
    Cho HK, Kozu H, Peyman GA, Parry GJ, Khoobehi B. The effect of aminoguanidine on the blood retinal barrier in streptozotocin induced diabetic rats. Ophthalmic Surg 1991;22:44–47.PubMedGoogle Scholar
  165. 165.
    Nakamura S, Makita Z, Ishikawa S, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997;46:895–899.PubMedCrossRefGoogle Scholar
  166. 166.
    Mitsuhashi T, Li YM, Fishbane S, Vlassara H. Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. J Clin Invest 1997;100:847–854.PubMedCrossRefGoogle Scholar
  167. 167.
    Vasan S, Zhang X, Zhang X, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996;382:275–278.PubMedCrossRefGoogle Scholar
  168. 168.
    Drickamer K. Breaking the curse of the AGEs. Nature 1996;382:211–212.PubMedCrossRefGoogle Scholar
  169. 169.
    Wolffenbuttel BH, Boulanger CM, Crijns FR, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998;95:4630–4634.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Helen Vlassara

There are no affiliations available

Personalised recommendations